559,500 Shares in Quanterix Corporation (NASDAQ:QTRX) Bought by Trium Capital LLP

Trium Capital LLP acquired a new stake in Quanterix Corporation (NASDAQ:QTRX - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 559,500 shares of the company's stock, valued at approximately $3,642,000. Quanterix accounts for approximately 0.5% of Trium Capital LLP's investment portfolio, making the stock its 14th largest position. Trium Capital LLP owned approximately 1.44% of Quanterix at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of QTRX. JPMorgan Chase & Co. grew its stake in Quanterix by 23.9% during the 4th quarter. JPMorgan Chase & Co. now owns 270,054 shares of the company's stock worth $2,871,000 after purchasing an additional 52,097 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Quanterix during the 4th quarter worth approximately $606,000. Price T Rowe Associates Inc. MD lifted its position in Quanterix by 18.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,878 shares of the company's stock worth $361,000 after acquiring an additional 5,385 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Quanterix in the 4th quarter valued at approximately $570,000. Finally, Jane Street Group LLC lifted its holdings in shares of Quanterix by 18.1% in the 4th quarter. Jane Street Group LLC now owns 55,947 shares of the company's stock valued at $595,000 after buying an additional 8,578 shares during the period. 86.48% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director David R. Walt purchased 123,990 shares of Quanterix stock in a transaction that occurred on Friday, June 13th. The shares were bought at an average cost of $6.14 per share, with a total value of $761,298.60. Following the completion of the purchase, the director directly owned 1,866,933 shares in the company, valued at approximately $11,462,968.62. This trade represents a 7.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William P. Donnelly bought 93,113 shares of the business's stock in a transaction that occurred on Friday, June 6th. The shares were acquired at an average price of $5.44 per share, with a total value of $506,534.72. Following the transaction, the director directly owned 139,094 shares of the company's stock, valued at $756,671.36. This represents a 202.50% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 463,113 shares of company stock valued at $2,625,444 in the last 90 days. 6.90% of the stock is currently owned by corporate insiders.

Quanterix Stock Up 3.8%

NASDAQ QTRX opened at $6.54 on Wednesday. The company has a market capitalization of $326.67 million, a PE ratio of -5.03 and a beta of 1.13. Quanterix Corporation has a 12-month low of $4.05 and a 12-month high of $16.74. The firm's 50 day moving average is $5.71 and its 200-day moving average is $7.14.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.16. The business had revenue of $30.33 million during the quarter, compared to analysts' expectations of $28.27 million. Quanterix had a negative net margin of 36.82% and a negative return on equity of 15.07%. As a group, sell-side analysts expect that Quanterix Corporation will post -0.98 EPS for the current year.

Analysts Set New Price Targets

QTRX has been the topic of a number of research analyst reports. Leerink Partnrs lowered Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Canaccord Genuity Group dropped their target price on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Wall Street Zen lowered shares of Quanterix from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Leerink Partners reaffirmed a "market perform" rating and issued a $8.00 price target (down from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. Finally, Scotiabank reissued an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Quanterix has an average rating of "Hold" and a consensus target price of $15.60.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.